Mutant superoxide dismutase 1 (SOD1) action within non-neuronal cells is implicated in damage to spinal motor neurons in a genetic form of amyotrophic lateral sclerosis (ALS).
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a progressive paralysing disorder characterised by degeneration of corticospinal, brainstem and spinal motor neurons in adulthood commonly leading to death within 2-5 years. Dominant mutations in the widely expressed antioxidant Cu, Zn-superoxide dismutase (SOD1) account for 20% of patients with inherited ALS and induce motor neuron disease-like phenotypes when expressed under the SOD1 promoter in transgenic mice and rats (1, 2) . Both active (eg. SOD1 G37R , SOD1
G93A
) and inactive (SOD1 G85R , murine SOD1 G86R ) mutants cause ALS, suggesting that toxicity to motor neurons is independent of dismutase activity (3) . Instead, motor neuron damage may be incurred by noxious SOD1 protein aggregates and non-dismutase oxidative reactions, leading to proposed abnormalities in axonal transport, neurotrophic factor support, mitochondrial function, ER stress and apoptosis with secondary glial cell responses contributing to glutamate-mediated excitotoxicity and neuroinflammation (4, 5) .
There is mounting genetic evidence for mutant SOD1 action within non-neuronal cells as a determinant of inherited ALS pathogenesis (6, 7) . Selective expression of SOD1 G93A in postnatal neurons under a Thy1.2 promoter triggered late-onset paralysis and motor neuron 4 To demonstrate non-cell autonomous contributions to inherited ALS neurodegeneration, mutant SOD1 and wild-type chimeras were created, revealing influence of adjacent spinal cord glia on motor neuron survival in mice (13) . Neither astrocyte nor microglial restricted expression of SOD1 G86R or SOD1 G93A mutants achieved by a GFAP promoter construct or transgenic bone marrow grafts into myeloid ablated PU.1 -/-mice, respectively, could initiate motor neuron disease though (14, 15) , consistent with the neuronal transgene excision data above. Instead, silencing SOD1 G37R expression in astrocytes or microglia using GFAP or CD11b promoter driven Cre activity delayed late progression, without affecting onset in mice (10, 11) . Concordant results were also obtained by diminishing SOD1 G85R levels in microglia, however both early and late phases of progression were slowed, suggesting that the antioxidant function of SOD1 mutants may counter toxicity to some degree in selective cell types (12) . Hence, central nervous system glial cells promote progression in transgenic ALS model mice, through an unidentified toxic mechanism(s).
Despite the emphasis on astrocytes and microglia, the role of peripheral cells in ALS remains less understood. Spinal motor neurons undergo retrograde degeneration in transgenic mutant SOD1 mice indicative of a dying-back axonopathy (16) , suggesting that molecular events distal to the ventral horn may be important in ALS. Although combined expression of SOD1 G37R endowed by the PrP promoter in neurons, astrocytes and muscle generates ALSlike symptoms (17) , Cre-mediated silencing of this mutant in skeletal myocytes using the MCK promoter did not modify disease parameters in mice (18) . In contrast, recent findings suggest that SOD1 G93A expression driven by the MLC promoter causes muscle pathology, but this may not fully recapitulate muscle atrophy characteristic of ALS (19) . An alternative mediator of the peripheral element to motor neuron degeneration may be Schwann cells, the major glial population of the peripheral nervous system. Consisting of non-myelinating cells of terminals (perisynaptic cells) and axons, as well as myelinating cells of axons, Schwann cells ensheath lower motor neuron projections facilitating real-time nerve impulse conduction.
These peripheral glia also serve essential non-conductive functions for motor neurons, including regulation of axonal calibre and transport, neurotrophic support for development, maturation and regeneration, and maintenance of neuromuscular synapses (20) , all key processes disrupted early in ALS models. The pathogenic role of Schwann cells is also reinforced by their primary involvement in peripheral neuropathies and Charcot-Marie-Tooth type 1 (CMT1) diseases with non-cell autonomous motor neurodegeneration (21) . We therefore sought to explore Schwann cells as possible candidates for mediators of mutant SOD1-induced toxicity in ALS.
RESULTS

The P0-Cx32 fusion promoter activates in Schwann cell cultures
We first generated expression constructs to selectively target human SOD1 production to Schwann cells. Wild-type (WT) or dismutase active mutant SOD1 (G93A) expression was driven by a splice promoter (P0-Cx32) consisting of a 1.1 kb rat myelin protein zero (P0)
promoter, that activates exclusively in myelinating Schwann cells (22) , fused to regulatory sequences of the human connexin-32 (Cx32) gene that direct high and constant transgene expression (23) (Fig 1A) . P0 promoter activity is also reported in non-myelinating Schwann cells including perisynaptic ones (24, 25) . Previously, this P0 promoter fragment alone achieved inconsistent reporter transgene expression in mice (26) . The fusion of 5'-untranslated sequence from Cx32 downstream of this promoter improved transgene expression level in vivo (23) . We used a novel construct here coupling ~4 kb genomic sequence from Cx32, including untranslated regions and translation-incompetent coding sequence to the P0 promoter, into which SOD1 cDNAs were cloned ( Fig 1A) . To validate these expression constructs, primary Schwann cells were cultured from postnatal mice and transfected with P0-Cx32-SOD1 vectors with an HA tag to distinguish endogenous protein, confirming expression in S100 intermediate filament-positive cells (Fig. 1B) . Transfected SOD1 was diffusely expressed throughout the cytoplasm of Schwann cells and notably, there was no prominent mislocalisation or aggregation of mutant SOD1 protein.
Immunoblotting was also used to establish a lack of high molecular weight mutant SOD1 oligomers indicative of aggregation in transfected Schwann cells (Fig. 1C) . This was validated using S100 and SOD1 immunohistochemistry on nerve sections of transgenic SOD1 G93A mice. SOD1 was diffusely localised within Schwann cells identified by nuclei and S100 immunoreactivity, in addition to axons ( 
Schwann cell-restrictive mutant SOD1 expression in mice
Preserved motor function and survival of transgenic P0-SOD1 G93A mice
All five lines of heterozygous transgenic P0-SOD1 G93A mice were studied longitudinally for denervation atrophy-induced weight loss, motor activity, clinical signs and survival.
Transgenic animals showed normal growth and lifespan within the observation period.
Locomotor function assessed by rotarod analysis was maintained in transgenic P0-SOD1 G93A mice past 1 year of age compared to wild-types (Fig. 3 ). In contrast, the reference line of transgenic SOD1 G93A mice were progressively paralysed and moribund by 123 ± 2 days (mean ± SEM). Moreover, all five transgenic founders survived to 2 years without evidence for muscle atrophy and motor dysfunction. Transgenic P0-SOD1 G93A mice bred to homozygosity were also symptom free. Hence, selective Schwann cell accumulation of mutant SOD1 did not provoke motor neuron disease-like symptoms.
Absence of neuropathology in transgenic P0-SOD1 G93A mice
We next examined transgenic P0-SOD1 G93A mice for spinal cord pathology at advanced age. 
MATERIALS AND METHODS
Construction of transgenic mice
Human SOD1 WT or SOD1 G93A cDNAs were PCR amplified from pEGFP-N1-SOD1 vectors (50) 
RT-PCR analysis
Mice were killed by lethal injection (Pentoject, IP). RNA was extracted from multiple tissues using the RNeasy kit (Qiagen) and 250 ng was reversed transcribed into cDNA using oligo(dT) primers and Superscript II (Invitrogen) according to manufacturer's instructions.
Human and murine SOD1 was PCR amplified using hSOD1F and hSOD1R primers above, and mSOD1F 5'-ACG TCC ATC AGT ATG GGG AC-3' and mSOD1R 5'-CCA CCT TTG CCC AAG TCA TC-3' primers, respectively.
Immunoblotting
Tissues were homogenised in RIPA lysis buffer containing 50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 0.1% (w/v) SDS, 1% (w/v) Na-deoxycholate, 1% (v/v) TX-100, 1% (v/v) protease inhibitors (Roche), 50 mM NaF and 0.2 mM Na 3 VO 4 by sonication at 50% output for 15 sec. 
Behavioural analysis
Locomotor function was assessed fortnightly using an accelerating rotarod (Rota-Rod 47600, Ugo Basile). Mice were trained once by three ramping sessions of 2-40 rpm for 5 min with
10 minute rest intervals and tested at ramping speed for a maximum of 5 min weekly. Disease onset was assessed retrospectively using the age of peak body weight as a measure of denervation muscle atrophy onset. Disease duration was determined as previously outlined . Early phase was the duration from peak weight to 10% or greater weight loss. Late phase was the interval from 10% or greater weight loss to endstage disease determined by onset of hindlimb paralysis defined by a failure to splay one or both hind legs when animals were suspended.
Primary cell culture and transfection
Primary Schwann cells were cultured from sciatic nerves of neonatal CD-1 mice. Nerves were dissected out, minced and incubated twice in 2 mg/ml collagenase (Sigma) and 0.025% Fluor conjugated secondary antibodies (1:1,000) for 2 hr before mounting for microscopy.
For immunoblotting, cells were transfected with pcDNA3-SOD1 plasmids (1 µg), lysed in RIPA buffer and soluble fractions analysed as above.
Statistical analysis
Neuronal and axonal counts were compared using one-way ANOVA with Tukey's post-hoc test. Rotarod data were analysed using repeated measures ANOVA. Onset and survival data were compared using Kaplan-Meier analysis with the log-rank test. Disease duration and densitometric data were subject to a Mann-Witney test or one-way ANOVA with Tukey's post-hoc test. Data are presented as mean ± SEM. All statistical tests were performed with GraphPad Prism software (version 3.02, GraphPad Software, San Diego, CA). 
